Phosphodiesterase 5 Inhibitor Market Report 2026

The phosphodiesterase 5 inhibitor market size has grown strongly in recent years. It will grow from $4.7 billion in 2025 to $5.02 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to aging male population, high prevalence of erectile dysfunction, clinical success of sildenafil and tadalafil, expansion of retail pharmacy networks, increased awareness of men’s health.

The phosphodiesterase 5 inhibitor market size is expected to see strong growth in the next few years. It will grow to $6.55 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to growth in lifestyle-related disorders, expansion of telemedicine prescriptions, increasing access to generic drugs, rising pulmonary hypertension cases, growth of digital healthcare platforms. Major trends in the forecast period include rising demand for erectile dysfunction treatments, increasing adoption of generic pde5 inhibitors, expansion of use in pulmonary arterial hypertension, growing online pharmacy distribution, increasing focus on patient convenience and privacy.

The rising prevalence of erectile dysfunction is expected to drive the growth of the phosphodiesterase 5 inhibitor market in the coming years. Erectile dysfunction (ED) is defined as the consistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. Its increasing prevalence is largely linked to hormonal imbalances, particularly low testosterone levels, which can impair sexual function and performance. Phosphodiesterase 5 inhibitors address erectile dysfunction by improving blood flow to the penis, enabling men to achieve and maintain an erection in response to sexual stimulation. For example, in December 2024, data from LloydsPharmacy Online Doctor, a UK-based community pharmacy, indicated that nearly 3.5 million prescriptions for the ED treatment Viagra were issued by the NHS in England in 2023, resulting in the distribution of approximately 25.5 million pills between September 2023 and August 2024. Consequently, the increasing prevalence of erectile dysfunction is contributing to the growth of the phosphodiesterase 5 inhibitor market.

The growing number of research studies and clinical trials is expected to drive the growth of the Phosphodiesterase 5 inhibitor market in the coming years. Clinical trials are research studies conducted with human participants to assess the safety, efficacy, and potential side effects of new treatments, drugs, or medical devices. This increase in research and trials is largely fueled by the rising demand for new therapies to meet evolving healthcare needs and improve patient outcomes. Phosphodiesterase 5 inhibitors support the clinical trial process by enabling more effective evaluation of therapeutic efficacy in conditions such as erectile dysfunction and pulmonary hypertension, thereby aiding the development of targeted treatments. For example, in December 2024, data from the Association of the British Pharmaceutical Industry, a UK-based pharmaceutical industry trade body, reported that the total number of industry-sponsored clinical trials initiated in the United Kingdom rose from 411 in 2022 to 426 in 2023. Additionally, Phase III trial initiations increased by 16.5% over the same period, climbing from 182 to 212. Consequently, the rise in research and clinical trials is expected to propel the growth of the Phosphodiesterase 5 inhibitor market.

Major companies operating in the phosphodiesterase 5 inhibitor market are focusing on developing innovative products, such as generic versions of Stendra, to increase market share and meet the growing demand for affordable treatments. Generic versions of Stendra contain the same active ingredient, avanafil, and help manage erectile dysfunction by inhibiting the PDE5 enzyme, which enhances blood flow to the penis. For example, in October 2024, Camber Pharmaceuticals, Inc., a U.S.-based pharmaceutical company, launched Avanafil tablets, phosphodiesterase type 5 (PDE5) inhibitors for erectile dysfunction. The tablets are available in 50 mg, 100 mg, and 200 mg strengths, each supplied in 30-count bottles. Avanafil works by improving blood flow to the penis during sexual stimulation, with effects typically observed within 15 minutes and lasting for over six hours.

Major companies operating in the phosphodiesterase 5 inhibitor market are Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Lupin Limited, Apotex Inc., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Mylan N.V. (Viatris), Hikma Pharmaceuticals PLC, Sandoz Group AG, Alembic Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Hetero Drugs Ltd., Seoul Pharma Co. Ltd.

North America was the largest region in the phosphodiesterase 5 inhibitor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phosphodiesterase 5 inhibitor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the phosphodiesterase 5 inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the PDE5 inhibitor market by increasing the cost of imported APIs and finished formulations used in erectile dysfunction treatments. These impacts are most pronounced in generic manufacturing hubs across Asia Pacific and Europe, where production volumes depend on cross border sourcing. Rising tariff related expenses have affected pricing strategies and margin structures for both domestic and export markets. This has influenced procurement planning and competitive positioning among manufacturers. However, tariffs have encouraged domestic drug manufacturing, expanded local production capacity, and improved long term supply chain resilience.

The phosphodiesterase 5 inhibitor market research report is one of a series of new reports that provides phosphodiesterase 5 inhibitor market statistics, including phosphodiesterase 5 inhibitor industry global market size, regional shares, competitors with a phosphodiesterase 5 inhibitor market share, detailed phosphodiesterase 5 inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the phosphodiesterase 5 inhibitor industry. This phosphodiesterase 5 inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A phosphodiesterase 5 (PDE5) inhibitor is a type of medication that blocks the enzyme PDE5, which breaks down cyclic guanosine monophosphate (cGMP), a molecule that helps relax smooth muscle and improve blood flow. These inhibitors are primarily used to treat erectile dysfunction and pulmonary arterial hypertension by enhancing blood flow in targeted areas.

The main types of phosphodiesterase 5 inhibitors include sildenafil, tadalafil, vardenafil, avanafil, and other related drugs. Sildenafil is used to treat erectile dysfunction and pulmonary arterial hypertension by relaxing blood vessels and increasing blood flow to specific areas of the body. These medications are available in various dosage forms, including tablets, injectables, and topical applications. They are used for conditions such as erectile dysfunction, pulmonary arterial hypertension, benign prostatic hyperplasia, and other related disorders. Distribution occurs through retail pharmacies, online pharmacies, and hospital pharmacies, serving a range of end users, including hospitals, specialty clinics, and home care settings.

The phosphodiesterase 5 inhibitor market consists of sales of products including sildenafil, tadalafil, vardenafil, avanafil, and lodenafil. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.